Category: Health

“Hong Kong Medical Block Chain MCHK” glory set sail

“Hong Kong Medical Block Chain MCHK” participated in the “20th China International Investment and Trade Fair”

1.On September 9, 2018, at the twentieth session of the China International Fair for Investment and Trade, more than 1,000 industrial and commercial groups, about 5,000 companies and more than 120,000 merchants from more than 110 countries and regions gathered in Xiamen .Medisun Medical Group participated in the forum.

The Medisun market team gathered at the Hong Kong medical block chain MCHK at the center booth of Xiajiahui

Terry Lierman (left), Chairman of Medisun Medical Group, and Mr. Danny Wong (right), Executive Chairman, at the “Hong Kong Medical Block Chain” booth

“Hong Kong Medical Block Chain MCHK” hosted the “Blockchain 3.0 Energizing Entity Economic Forum”
Organized by the China Investment Association, Tsinghua x-lab Ivy League Research Institute and Medisun Medical Group’s “Block Chain 3.0 Energizing Entity Economic Forum” became a highlight of the current Xiamen Fair.
Blockchain 3.0 empowers the real economy and has become a new consensus in China’s blockchain industry. Blockchain 3.0 represents the Internet of Things-based blockchain 3.0 technology that truly links the digital economy to the real economy to form a complete blockchain technology, business and financial services ecosystem for the service industry.

Terry Lierman, Chairman of Medisun Medical Group, addressed the investment forum

Mr. Danny Wong (first from right), Chairman of the Medisun Medical Group, signed the strategic cooperation of the “Ticket Reform Laboratory”

Terry Lierman, Chairman of Medisun Medical Group, introduced the Hong Kong medical block chain MCHK

Terry Lierman, Chairman of the American Medical Group, said that the most critical factors in the health care system are Transparecny, Quality and Access. The reason why the US medical system does not have such an accident in China is because the US FDA adheres to the standard approval and monitoring process for medical products. This is the effectiveness of the medical system. The Hong Kong medical blockchain will also be reliable. The medical platform is based on blockchain technology. Any vaccine products and medical products are produced, circulated and used on the MCHK platform are transparent and traceable.

“Hong Kong Medical Chain Chain MCHK”, as the Hong Kong medical service public chain, is based on the collection of 500 advanced medical institutions in Hong Kong. It integrates 5,000 medical institutions in the Greater Bay Area within three years, and uses the blockchain technology as a framework to integrate Medisun Medical The Group’s rich clinical research and development technology and experience in regenerative Medisun have enhanced the trust and consensus of the children’s vaccine and cancer vaccine industry, promoted the integration and upgrading of the medical industry in Dawan District, and achieved the first to meet the international standard level in the “9+2 City” medical service system in Dawan District.

“Hong Kong Medical Block Chain MCHK” won the “Blockchain Innovation Enterprise Award”

This forum held the awarding ceremony of “Blockchain 3.0 Encouraging Entity Economy Top Ten Innovative Enterprises”. “Hong Kong Medical Block Chain MCHK” won the award as the latest medical health platform based on blockchain technology.

Mr. Danny Wong (third from left), Executive Chairman of Medisun Medical Group, received the award.

Launching Ceremony of “Hong Kong Medical Blockchain MCHK”

On September 10th, the launching ceremony of the Hong Kong medical block chain MCHK was held in Xiamen. The chairman of the group, Terry Lierman, and the executive chairman of the group, Mr. Danny Wong, co-chaired and opened the champagne. The marketing team raised a toast to celebrate this memorable day!

Hong Kong Medical Block Chain MCHK Launch Ceremony

MCHK “Hong Kong Medical Block Chain” Hong Kong Medical Services Public Link is a joint venture of Medisun Medical Group.

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative product technology, as well as quality hospitals and treatment centers. Medisun has long-term cooperation with the Johns Hopkins Life Science Center and the Harvard University Stem Cell Institute, working on the investment and research and development of new technologies in the field of regenerative worldwide, and conducting clinical trials in many well-known hospitals in mainland China and Hong Kong; In cooperation with Tsinghua University, Medisun established the “Medical Institute of Cell Technology of Tsinghua University” and “Medical University Tsinghua University Regenerative Medisun Industry Fund”.

The Medisun Regenerative Centre is located in Kowloon Bay, Hong Kong. It has an international GMP standard medical laboratory, cancer treatment center and anti-aging center. It provides immune cell therapy, a variety of stem cell health treatments, a number of child and adult vaccinations and a full range of biomedical products. Testing to provide customers with the most predictable health protection.

For more information, please visit http://www.medisun.hk/

Qingkong Crossing Digital Industry Fund Launched.

Blockchain 3.0 votes change consensus unveiled at 9.8 CIFIT

On September 9th, the 20th China International Investment and Trade Fair – 2018 blockchain technology enabling entity economic investment forum was held in Xiamen, this forum was hosted by China Investment Association Investment Advisory Committee, Tsinghua x-lab Ivy The Chain Alliance Research Institute and the Shun Tak T30 Parent Fund jointly hosted.
Chairman of the China Investment Association Investment Advisory Committee, Mr. Huiye Zhu, Secretary General of the China Electronic Chamber of Commerce Blockchain Special Committee Mr. Li Yinke, the president of Tsinghua x-lab lvy Chain Research Institute, Mr. Zhong Hong, Partner of the Crossing Fund, Mr. Terry Lehman and Mr. Danny Wong, Co-founders of Medivh Medical Group, Mr. Chen Jianren, Chairman of the Board of Directors of Xiaobawang Group, Mr. Yang Yun, Chairman of Board of Directors of Hong Kong Dachang Financial Technology Group, Jinhaohao Technology Holdings Mr. Jin Qiu Bing, co-founder of the group, Mr. Li Shuai, CEO of Core Cartoon Technology, and Mr. Li Hongkun, President of Diplo Continental Technology, attended the forum,the scale of this year’s Xiamen meeting is huge. More than 1,000 industrial and commercial groups, more than 5,000 companies and more than 120,000 merchants from more than 110 countries and regions gathered in Xiamen. This forum has become a highlight of this year’s Xiamen Fair. The “Qingdao Crossing Digital Industry Fund and Blockchain 3.0 Energizing Entity Economy Baicheng Baihui Project” jointly initiated by Tsinghua x-lab Qingteng Chain Research Institute, Qingkong Crossing Fund and Shunde Fund, officially launched, the future It will cooperate with 100 cities and 100 industry chambers of commerce to develop blockchain 3.0 to enable the real economy lecture hall, and find successful cases of blockchain technology application in the industry.

The forum also carried out the ceremony of “Strategic Cooperation Signing of Block Chain 3.0 vote change Laboratory” and the awarding ceremony of “Top 10 Innovative Enterprises in Block Chain Energizing Entity Economy”. The award-winning enterprises included Xiao bawang Ruyi Culture Technology Co., Ltd. (BWTT), Hong Kong Medici Medical Holding Group (MCHK), Hong Kong Dachang Financial Technology Co., Ltd. (BMY), Jinhaohao Technology Holdings (DJMT), Core Cartoon Technology (SWWT), Hong Kong Zangjintang Biotechnology ( TOT) Tiebao Continental Technology (TBB), Property Chain Technology (TCT), Shunde Parent Fund (T30), and Good Skin Biotechnology Co., Ltd. (DST).

In the speech, the Chairman of the China Investment Association’s Investment Advisory Committee, Mr. Zhu Huizhen, said that the blockchain technology itself can promote the development of the real economy. We support new technologies to bring new kinetic energy to the economy, and we hope that more entities can Participate in the practice of this blockchain 3.0 ticket reform, and make more successful cases of blockchain empowerment of the real economy.

Li Yinke, secretary general of the China Electronics Chamber of Commerce Blockchain Committee of the Ministry of Industry and Information Technology, said in his speech that the blockchain as a bottom layer technology has already made successful industrial applications in certain areas of financial technology. Core cartoon is a good example. Hope In the future, relying on the power of the Chamber of Commerce to promote more blockchain technology companies to empower the real economy.

In the theme sharing, the president of Qinghua x-lab, has proposed a blockchain 3.0 to empower the real economy, which has become a new consensus in China’s blockchain industry. Blockchain 3.0 represents the IoT-based blockchain 3.0 technology that truly links the digital economy to the real economy to form a complete blockchain technology, business and financial services ecosystem for the service industry.

The blockchain 3.0 vote change laboratory is an innovative experimental platform that promotes the blockchain 3.0 to empower the real economy. It will integrate experts in seven fields of politics, production, learning, research, investment, innovation and media to form a national ministry. The local government and industry think tanks aim to promote the transformation and upgrading of China’s current real economy, and jointly promote the research and implementation plan of the blockchain 3.0 industry vote change theory and the implementation of the blockchain industry service organization. The real economy enterprises are fully docked, and a complete vote change plan will be formed before the end of 2018, and the first batch of vote change pilot zones will be built in the country with various industry associations.

Qingkong Daokou Digital Industry Fund & Blockchain Empowerment Entity Economy Baicheng Baihui Launched.

The president of Shun Tak T30, the co-founder of the vote change lab, Hu Jiesen, made a wonderful topic sharing in the forum. He said that the essence of blockchain technology is to solve the problem of trust and consensus.

“Qingkong Daokou Digital Industry Fund”, relying on the technology and financial resources of Tsinghua Holdings and Tsinghua Wudaokou Finance College, will focus on using the power of technology and capital to help “blockchain vote change laboratory” and establish blockchain empowerment The real economy innovation ecology. The ticket-changing public chain “chain ticket” project currently being hatched is supported by the blockchain 3.0 underlying public chain technology, which will serve the assets of the entity, and relieve the inventory backlog and financing difficulties in the form of digital tickets. The problems faced by the entity enterprises, the current property chain ticket project has been applied in the medical and insurance industry. In the 2018, when the real economy encountered major challenges, the “blockchain 3.0 vote change laboratory” is incubating a batch of industry application success stories. And will rely on the strength of domestic industry associations and local governments to jointly empower the real economy.

vote change lab launching ceremony

Group photo of some guests at the meeting

For more information, please visit http://www.medisun.hk/

Medisun launched the “Hong Kong Regenerative Medisun Association”

On May 28, 2018, the Hong Kong Regenerative Medisun Association, which was initiated by representatives from the Hong Kong Regenerative Medisun Industry and academic circles, was formally established under the auspices of the Medisun Medical Group.

Hong Kong Regenerative Medisun Association goals

The Hong Kong Regenerative Medisun Association was founded by experts, scholars, industry representatives and people of insight in the field of regenerative Medisun in Hong Kong and around the world. The purpose of the association is to establish a consensus platform for the regenerative Medisun industry in Hong Kong, promote the development of the regenerative Medisun industry, encourage and promote international cooperation, and propose to the Hong Kong SAR government the recommendations of the regenerative Medisun industry on industry regulations and actively influence industry rules. The establishment and improvement of the company provides effective technical and management advice to the Hong Kong government, Hong Kong public health agencies and companies in the industry.

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

On the afternoon of May 28, representatives from Hong Kong’s medical health, regenerative Medisun and biotechnology fields, doctors, pharmacists, chemists and university researchers gathered to discuss and elect the first council of the Hong Kong Regenerative Medisun Association.They read the charter of the association and clarify the duties of the board. At the same time, they have had a heated discussion on the regulatory documents issued by the Hong Kong SAR Government on Advanced Therapy Products. They agreed to regulate the direction of document guidance and proposed a number of issues that need to be clarified, including:

1. Professional qualifications required by the licensee of the Regenerative Medisun and Stem Cell Research and Development Organization;

2. Advanced Therapy Products is regulated by the Pharmacy and Poisons Ordinance (Cap. 138). However, since the production process and user definition of cellular products and pharmaceutical products are different, they should be clarified accordingly;

3. With reference to the requirements of the international GMP/PICS standard, which standard should be achieved in the cell laboratory qualification of existing regenerative Medisun institutions;

4. After the specific regulation is in force, whether there should be a transition period, so that the industry has time to adjust and cooperate;

5. Submit the Advanced Therapy Products comments and submit them to the Hong Kong Department of Health.

Member of the First Council of the Hong Kong Regenerative Medisun Association

Position	Name	Qualifications
Chairman	Danny Wong Mr. Wang Xiaofeng	Founder and Chairman of Medisun Medical Group, years of investment experience in the field of regenerative Medisun, understanding the development and trends of the biotechnology industry
Vice President	Joseph Wang  Dr. Wang Qiyuan	Registered as a doctor, founder of the Hong Kong Stem Cell Center, enriching the clinical experience of regenerative Medisun
Vice President	David Leung Mr. Liang Yaoming	Registered pharmacist, familiar with pharmaceutical regulations and GMP requirements
Vice Chairman	Gregory Cheng Professor Zheng Yanming	Hematology expert, Professor of the University of Macau Health Sciences
Director | Treasurer	Kenneth Lee Dr. Li Zhisheng	Registered as a doctor, B Q Anti-aging Center Consultant
Director	Philip Choy Dr. Cai Shaolong	Ph.D. in Natural Medisun, Madison Biomedical Director
Director	Daniel Tam Dr. Tan Yizhu	Registered as a medical laboratory technologist, director of the Trans-Olympic Blood Bank Laboratory, focusing on cell culture technology for many years
Director	Vivien Leung Ms. Liang Yiqun	Registered as a medical laboratory technologist, manager of the Trans-Olympic Blood Bank Laboratory, familiar with quality management
Director	Chris Wong Dr. Huang Libao	Registered as a medical laboratory technologist, director of HKMDPC, molecular biodiagnostic expert
Secretary	Sidney Tam Dr. Tan Guozhen	Chief Executive Officer, Life Clinic, Health Management Consultant
Secretary	Allen Chan Mr. Chen Yuxin	Registered as a medical laboratory technologist, familiar with quality management

The first meeting of the Hong Kong Regenerative Medisun Association (May 28, 2018)

Hong Kong Regenerative Medisun Association’s recent work plan

Next, the Hong Kong Regenerative Medisun Association will issue letters to the organizations including the Hong Kong Department of Health, the Hong Kong Stock Exchange, the Hong Kong University Biomedical Science, Life Sciences, and the Global Regenerative Medisun Alliance (ARM). include:

1. Announced the official establishment of the Hong Kong Regenerative Medisun Association

2. Announce the initial membership list of the Hong Kong Regenerative Medisun Council, association charter, association vision and goals

3. Call for the support and participation of experts, scholars and industry representatives from Hong Kong and around the world

4. Propose to the Hong Kong Government to clarify regulatory regulations on Advanced Medisun and Advanced Therapy Products

Special thanks

Thank you for taking the time to attend the representatives of the institutions, including:

Medisun Medical Group | Medisun Reproductive Medisun Center

Hong Kong Life Science and Technology Group Co., Ltd.

Standard Pathology Laboratory Co., Ltd.

BIH

Living Tissues company limited

BIB Health Care Centre

Hongxin Medical Center

Austa beauty

Hong Kong International Regenerative Medisun Centre

HKMPDC

Huixin Technology

Guangzhou Biological Institute

Trans-along cord blood bank

Hong Kong Stem Cell Center

Life Length

Biocell

Cordlife

For more information, please visit http://www.medisun.hk/

The famous American vaccine company Profectus settled in Hong Kong

First recommend HPV cervical cancer treatment vaccine

BALTIMORE, MARYLAND, USA and HONG KONG, April 20, 2018

Profectus Biotech and Medisun Medical Group today announced the opening of a new joint venture in Hong Kong. The primary mission of the new company, ProMed BioSciences, Ltd., is to establish a leading vaccine company focused on the development of preventive and therapeutic vaccines for infectious diseases and cancer. The joint venture will leverage Profectus’ vaccine development expertise, clinically proven vaccine platform technology and a developing vaccine product line, in line with Medisun’s expertise, established clinical network and market access capabilities, expected in the second half of 2018 to put into operation.

The company’s first product development program will focus on the development, production and commercial application of prophylactic and therapeutic vaccines for HPV (human papillomavirus)-related lesions and cervical cancer [based on PBSVax® technology developed by Profectus]. ProMed BioSciences also plans to develop and treat hepatitis C virus (HCV), hepatitis B virus (HBV), herpes simplex virus (HSV), respiratory syncytial virus (RSV), and human immunodeficiency virus (HIV). Chikungunya and Zika, as well as personalized vaccines to treat cancer. The joint venture is expected to launch new vaccines in their respective markets, which will help promote the development of new vaccines, but ultimately the goal is to benefit patients around the world.

Mr. Jeffery Meshulam (first from left), President of Profectus Biotechnology, Mr. Terry Lierman (second from left), Chairman of Medivh Medical Group, and Mr. Danny Wong (fourth from right), founder and executive chairman of Medisun Medical Group, at Profectus ,USA.

– Long-term strategic cooperation to address the huge demand for prevention and treatment of infectious diseases and cancer in Asia

-Profectus’ expertise in vaccine development and platform technology, combined with Medisun’s localized expertise and experience, to establish a leading Hong Kong vaccine company focused on serving Asia

“This strategic cooperation will help establish Profectus’ business in Hong Kong and China. Through close cooperation with Medisun, we can assist Hong Kong and China to develop advanced vaccine technology to help prevent and treat Asian patients. Mr. Jeffrey Meshulam, President of Profectus, said, “We are pleased to be able to work with recognized local partners to achieve the highest standards of scientific research and development integration and medical services.”

“This collaboration will help Profectus and Medisun to jointly produce life-saving vaccines for infectious diseases and cancer, and address the huge medical needs that have not been met in Hong Kong, China and Asia.” Mr. Danny Wong, founder and executive chairman of Medisun Medical Group, said “ProMed BioSciences will leverage Profectus’ expertise in vaccine development and technology, combined with Medisun’s local expertise and close links with healthcare facilities in Hong Kong and China, and government medical regulatory agencies to develop vaccines to provide leadership for Asian patients disease prevention and treatment programs.”

ProMed BioSciences will focus on the following:

• Conduct technical research in Hong Kong or China

• Conduct clinical trials in Hong Kong or China

• Promote the expansion of Medisun Medical Center

• Develop vaccines to address disease prevention needs

• leverage to maximize the expertise of both partners

Mr. Jeffery Meshulam, President of Profectus Biotechnology (first from left), Mr. Terry Lierman, Chairman of Medisun Medical Group (first from right), Mr. Danny Wong, founder and executive chairman of Medisun Medical Group (middle), at the US headquarters of  Profectus.

About ProMed BioSciences

ProMed BioSciences Limited is a joint venture between Profectus BioSciences (USA) and Medisun Medical Group (Hong Kong) in Hong Kong to develop and conduct new vaccine clinical trials and commercial applications to address infectious diseases and cancer in Asia with the huge demand for prevention and treatment.

About Medisun

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as quality hospitals and treatment centers. Medisun invests extensively in the fields of regenerative and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun and Harvard University Stem Cell Research Institute, Johns Hopkins Medical School Life Science Center, Tsinghua University and other institutions have long-term cooperation plans to jointly invest in regenerative and stem cell therapy technology, with Medisun as a cooperative business The holding entity and holds global intellectual property rights. Medisun and the University of Maryland’s Institute of Human Virology (IHV) set up a technology clinical trial and development platform for viruses and cancer. Based on the Medisun Biomedical Laboratory in Hong Kong, Radiation will jointly build medical clinics in China and Asia. The experimental resource network promotes the world’s largest clinical research and development platform for virus research and cancer treatment technology. The Medisun Reproductive Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments.

For more information, please visit http://www.medisun.hk/

About Profectus BioSciences

Profectus BioSciences is a clinical stage vaccine development company focused on developing new vaccines for infectious disease and cancer prevention and treatment. The Profectus vaccine is based primarily on the company’s proprietary VesiculoVax™ and DNA vaccine technology platform. By simply using the VesiculoVax™ vaccine alone, B cells can be rapidly expanded to provide protection against emerging infectious diseases that threaten public health and biodefense mechanisms, such as Ebola, Marburg, Chikungunya, Zika virus, equine encephalitis virus, and respiratory syncytial virus. When VesiculoVax™ is used as a vaccine when the immune system is launched with the best pDNA vaccine, the Vesiculo Vax™-directed vaccine expands the triggered T cells into effector cells, which are ideal for attacking virus-infected cells and cancer. Current projects using the Prime / Boost Vaccine System (PBS Vax™) strategy include hepatitis B virus (HBV), human papillomavirus (HPV), herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus ( HIV). Partners and collaborators include UTMB’s Galveston National Laboratory, Yale University, University of Maryland Human Virology Institute, HIV/AIDS Vaccine Immunology Center, National Cancer Institute, National Institutes of Health AIDS Division, Bill And the Melinda Gates Foundation, the International AIDS Vaccine Initiative, the AIDS Vaccine Trial Network and the AIDS Clinical Trial Group. Profectus is funded by Cross Atlantic Capital Partners (“XACP”) in Radnor, Pennsylvania. The main investor in XACP is the Pennsylvania Public School Employees Retirement System (“PSERS”). For more information, please visit www.profectusbiosciences.com

Medisun Regenerative Medical Center and Health Summit

Cancer Vaccine | White House Cancer Lunar Plan | Cancer Proton Beam Treatment

ShenZhen- Hong Kong-GuangZhou

The Medisun Medical Health Summit, co-sponsored by Medisun Regenerative Medical Group, New Life Group and Sunshine Medical Group, was held in Shenzhen, Hong Kong and Guangzhou from September 6 to 9, 2017. The theme of this summit is centered around the prevention and treatment of cancer. The authoritative release of cancer vaccine is the strongest focus of this summit.  

Medisun Medical Group has invited a number of authoritative scientists, medical experts, industry leaders, government agency representatives, business leaders and socialites from the United States, Europe, Japan, Hong Kong and Mainland China to collaborate on cancer prevention worldwide. Leading medical health consultations such as therapeutic technologies, industry regulatory development, and medical platform construction have been fully explored. Nearly 5,000 entrepreneur representatives, medical experts and doctors from the Chinese health industry participated in the listening and sharing.

Dozens of media interviews and reports at the summit

Madison Cancer Vaccine Launch Ceremony

Chairman Danny Wong said: “The advent of cancer vaccine is the strongest gospel of cancer prevention!”

According to the World Health Organization (WHO), approximately 14 million new cancer cases are diagnosed each year worldwide, and this number is expected to reach 21 million by 2030. As global treatment costs rise, cancer prevention measures are becoming more and more important, which has also made cancer prevention and treatment a high-profile international issue. Medisun’s comprehensive introduction of cancer vaccines is undoubtedly the strongest gospel for cancer prevention. The WT1 gene is a gene representing tumorigenesis in humans, and all human cancers are associated with this genetic mutation. The Nobel Institute of Ecological Medical Sciences has discovered a pathway to inhibit mutations in the WT1 gene, which can be vaccinated to produce memory T cells that inhibit WT1 gene mutations, which are immune to humans.

In addition, Medisun is also committed to the development and clinical use of a variety of other vaccines. Most of the vaccine technology comes from the United States, investing in rapid response to the pandemic virus and cancer control vaccine technology platform, with a market size of more than 2 billion US dollars. The vaccines invested by Medisun can be modularized in Asia and China to produce vaccines that are fully compliant with the United States. Including: Zika virus, Chikungunya fever, Zika/Chikununya heat combination, Ebola virus, human papillomavirus HPV treatment vaccine, head and neck cancer, cervical cancer, cervical lesions, simple Herpesvirus HSV, hepatitis C virus HCV, hepatitis B virus HBV,etc.

Mr. Danny Wong, Chairman of Medici Medical Group, was interviewed by the media about the release of cancer vaccine.

Chairman Danny Wong specifically said: “China’s rapid economic development over the past 20 years has been accompanied by a wave of globalization. China has integrated into the international community in various fields. At the same time, China has introduced high-standard medical technologies and services from Europe, the United States and Japan. It is our mission to make full use of Hong Kong’s advantages as a mature international metropolis and special geographical factors to provide the world’s most advanced medical care to the people of the motherland.

On-site participants actively asked questions from the cancer vaccine and new cancer treatment technologies to participate in the seminar.

Medisun participates in the White House Cancer Month Plan

Mr. Terry Lierman said: “The greatest progress and breakthrough of mankind is the birth of cancer vaccine!”

Mr. Terry Lierman, a core member of the White House Cancer Month Program, the NIH of the National Institutes of Health, and the founder of the FDA Board of Directors and director of the Meditech Group, said that cancer landing is an amazing cause. It is planned to complete the treatment of 20,000 cancer patients with 60 different technologies worldwide by 2020. This is a task that would have taken at least 10 years to achieve, and we will now achieve it in 5 years. The cancer “moon landing plan” advocated by former US President Barack Obama in 2016 is also the focus of this summit. The plan is led by former Vice President Joe Biden. The goal is to break the boundaries that hinder the cooperation of researchers and accelerate the research of cancer diagnosis and treatment in the future. 5 years to double the progress of anti-cancer research. The six major US cancer “moon landing programs” include cancer vaccines, high-sensitivity cancer early detection, immunotherapy and combination therapy, single-cell genomic analysis of cancer cells and tumor microenvironment cells, new treatments for childhood cancer, and enhanced data. shared. To this end, the United States and Canada, Hong Kong, Germany, Switzerland, Japan, South Korea and other countries, the first-class research units to establish cooperative relations, large-scale joint cancer research and treatment, toward precision Medisun. The Medisun Medical Group is a member of the Cancer Month Program and will also participate in this historic mission.

Mr. Terry Lierman talks about McGrady’s participation in the White House Cancer Month Plan

Medisun introduces Mayo proton beam therapy

Dr. Michael Haddock said: “The Mayo proton beam is a great advancement in the precise treatment of cancer!”

As the Asian Medical Service Center of the Mayo Clinic in the United States, Medisun invited Dr. Michael Haddock, Chairman of the Mayo Radiation Oncology Clinical Practice Committee and Vice Chairman of the American Society of Surgery Oncology (ACOSOG) Committee to talk about radiotherapy for cancer. Dr. Haddock talked about the current Proton Bean, the world’s leading cancer radiotherapy technology, Mayo currently has the most authoritative equipment, operations and medical team for global proton beam therapy. Mayo’s proton beam therapy program is the exclusive feature of pen beam scanning. It can accurately target tumors and prevent healthy tissues from being affected, thus achieving ideal cancer treatment, especially for treating children with cancer. For cancers with high mortality and lung cancer, proton beam therapy has obvious advantages compared with traditional radiotherapy.

At the Hong Kong Summit, Dr. Michael Haddock (left), the authoritative doctor of Mayo cancer proton beam therapy, answered questions from guests at the scene.

Dr. Michael Haddock (left) and Mr. Terry Lierman (right), the authoritative doctors of Mayo cancer proton beam therapy, at the Guangzhou Summit.

Japanese NKT immune cell therapy

Dr. Degang said: “Cancer vaccine and NKT immune cell therapy are the strongest partner in cancer prevention and treatment!”

Haruhiro Tokuoka, CEO of Riken Immunization and Reproductive Medisun, Japan, Dr. Degang Governing, talked about immunotherapy for cancer. Japan has always been a pioneer in cancer immunotherapy and has extensive clinical experience. Japan Riken and Medisun have worked closely together and established the Medisun Precision Medical Joint Venture, which applies NKT immunocytotherapy outside the traditional cancer treatment to clinical treatment of various types of cancer in the early, middle and late stages, and has clinically proven to greatly improve cancer patients. High quality of immunotherapy at the same time as quality of life with almost no side effects.

Dr. Kazuoka Kazuo of Japan at the Hong Kong Summit to explain the effectiveness of NKT immune cell therapy in clinical treatment of cancer.  

Dean He Jianxing (second from right) of Guangzhou Medical First Hospital visited the Guangzhou Summit and participated in Dr. Degang Zhiwei (third from left) on cell immunotherapy

Precision Medisun and anti-cancer cancer

Ms. Yanglan said: “As a mother, I chose to give my daughter a HPV cervical cancer vaccine; now the launch of the cancer vaccine is even more exciting!”

In today’s society, everyone is tired of work, and it is often the easiest to ignore their good habits, which leads to the emergence of various diseases . In fact, “health is the first wealth of life”, Emerson’s famous interpretation perfectly interpreted the importance of a healthy life to people. Ms. Yang Lan, a well-known Chinese media person, attended the summit as a guest and shared ideas about health and happiness with the guests. She said that the pain caused by cancer patients to the family cannot be expressed in words, and health is good for every family. Precious, we need to follow the development of science and technology to update our medical knowledge. Nowadays, precision Medisun has brought us new choices. While we are not blindly following, we should fully understand the physical condition of ourselves and our families, and choose the right medical health program for ourselves.

Ms. Yang Yu shared about cancer treatment.  

Ms. Wu Shuqing, the Honorary Director of the World Trade Center Association and the Standing Committee of the National Committee of the Chinese People’s Political Consultative Conference, was unable to visit the summit due to the temporary overseas meeting. She also sent a congratulatory message to the summit and congratulated Chairman Danny Wong of the Medisun Medical Group: “The summit has deepened Hong Kong with the Chinese mainland again, we are highly concerned about the medical and health industry. Therefore, I believe that Medisun Medical Group will continue its leading position in the field of medical and health care. Since the beginning, I have seen the entire team of Medisun under the leadership of Chairman Danny Wong. Unremitting efforts and dedication, I am convinced that today’s event is only the beginning, I hope that more results will be shared with the whole society.”

As a pioneer in the field of stem cells, cancer prevention and treatment in the world of regenerative , Medisun Medical Group has been committed to introducing the world’s leading cancer prevention and treatment technologies and providing the most advanced, professional and excellent medical and health services to the society. The release of the cancer vaccine is a revolutionary advancement in the field of cancer prevention. Ancient smallpox is terminally ill, and now a single shot of smallpox disappears; in the past, hepatitis B was terminally ill, and now a vaccine is immunized for life; yesterday, cancer is terminally ill, and today’s cancer vaccine keeps cancer away. Time is advancing and science is progressing. We must have a mentality of accepting progress. We believe that cancer prevention can provide shelter for the family and the health and well-being of  society.

Stay tuned: Hong Kong’s latest publication “CAPITAL” magazine in September, cover story “Mr. Danny Wong, Chairman of Medisun Medical Group” and cover story “New Revolution in Medical Industry”.

You can contact the Hong Kong Medisun Regenerative Medical Center to receive a magazine. Contact as below:

Phone: +(852) 2582 0188

Email: info@medisun.hk

WeChat: medisuninfo

Website: www.medisun.hk

****************************************

Medisun Medical Group

Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative  products, as well as top hospitals and treatment centers. Located on the 25th floor of Ao Teng Plaza, Kowloon Bay, Hong Kong, the Medisun Reproductive Centre has a 50,000-square-foot stem cell GMP production facility, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to be rigorous and professional. The development process provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. More than 3,000 biomedical tests provide the most predictable health protection for the health of our clients. Medisun has been fully supporting the development of the new life and health platform, and is committed to the deepening of the new products and technologies of regenerative Medisun through this platform, truly benefiting the health of the whole society.

For more details, please visit http://www.medisun.hk/